Anixa Biosciences Inc. (ANIX)
$2.90
$-0.17
(-5.54%)
As on 08-Sep-2026 16:00EDT
Market cap
$104 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
7.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-8.8
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
34,023,063
10 Years Aggregate
CFO
$-41.02 Mln
EBITDA
$-86.12 Mln
Net Profit
$-93.38 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
| -7.1 | -15.2 | 16.9 | -2.4 | -4.5 | -11.0 | -2.0 |
|
BSE Sensex
| -10.7 | -3.7 | 1.8 | -6.4 | 4.5 | 5.3 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
| 34.5 | -40.0 | -8.7 | 43.1 | -3.3 | -6.4 | -16.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Anixa Biosciences (ANIX)
|
2.9 | 104.5 | 0.0 | -10.1 | -- | -67.4 | -- | 7.2 |
| 1.7 | 8.0 | 0.0 | -8.8 | -- | -373.2 | -- | 10.8 | |
| 72.3 | 11,358.4 | 1,215.0 | 181.9 | 20.3 | 9 | 62.4 | 5.4 | |
| 2.1 | 16.9 | 0.0 | -22.1 | -- | -0 | -- | 1.9 | |
| 5.1 | 72.5 | 59.4 | -1.2 | -1.6 | -30.5 | -- | 17.7 |
Shareholding Pattern
View DetailsAbout Anixa Biosciences (ANIX)
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T... cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California. Read more
-
CEO, Chairman & Co-Chair of CBAB
Dr. Amit Kumar Ph.D.
-
CEO, Chairman & Co-Chair of CBAB
Dr. Amit Kumar Ph.D.
-
Headquarters
San Jose, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Anixa Biosciences (ANIX)
What is the current share price of Anixa Biosciences Inc (ANIX) Today?
The share price of Anixa Biosciences Inc (ANIX) is $2.90 (NASDAQ) as of 08-Sep-2026 16:00 EDT. Anixa Biosciences Inc (ANIX) has given a return of -4.5% in the last 3 years.
What is the current PB & PE ratio of Anixa Biosciences Inc (ANIX)?
Since, TTM earnings of Anixa Biosciences Inc (ANIX) is negative, P/E ratio is not available.
The P/B ratio of Anixa Biosciences Inc (ANIX) is 7.15 times as on 04-Sep-2026, a 34 premium to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-- |
-- |
2024 |
-- |
-- |
2023 |
-- |
-- |
2022 |
-- |
-- |
2021 |
-- |
-- |
What is the 52 Week High and Low of Anixa Biosciences Inc (ANIX)?
The 52-week high and low of Anixa Biosciences Inc (ANIX) are Rs 5.46 and Rs 2.32 as of 09-Sep-2026.
What is the market cap of Anixa Biosciences Inc (ANIX)?
Anixa Biosciences Inc (ANIX) has a market capitalisation of $ 104 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Anixa Biosciences Inc (ANIX)?
Before investing in Anixa Biosciences Inc (ANIX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.